SXTC - China SXT Pharmaceuticals receives 180-day extension to regain Nasdaq minimum bid price compliance

2023-05-10 11:02:22 ET

• Specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces, China SXT Pharmaceuticals ( NASDAQ: SXTC ) receives Nasdaq grant for another 180 calendar days extension, or until October 30, 2023, to regain compliance with minimum bid price requirement.
• The company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period.

For further details see: